Tempest Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $9.14M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 4, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | After market close | – | $0.34 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | After market close | – | $-2.53 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 30, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 5, 2025 | Before market open | – | $-0.79 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 11, 2025 | After market close | – | $-2.07 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | After market close | – | $-3.16 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 27, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | After market close | – | $-0.41 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | After market close | – | $-0.42 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | After market close | – | $-0.36 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 19, 2024 | After market close | – | – | – |
Press releases
Announcements Tempest Therapeutics filed with the SEC
PRESS RELEASE, DATED SEPTEMBER 23, 2026, FURNISHED HEREWITH
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Tempest Secures Exclusive Option to License Clinical-Stage
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Tempest Reports Second Quarter 2026 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Tempest Reports First Quarter 2026 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Tempest Presents Clinical Update at ISCT 2026 Annual Meeting
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
® Developing Advanced Therapies for Cancer Patients
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Tempest Reports Year End 2025 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
for Cancer Patients February 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private
Unregistered share sale · Other events · EX-99.1 to Form 8-K
Tempest Reports Third Quarter 2025 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Tempest Reports Second Quarter 2025 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Tempest Reports First Quarter 2025 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical
Agreement terminated · Regulation FD disclosure · EX-99.1 to Form 8-K
Tempest Reports Year End 2024 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Tempest Reports Third Quarter 2024 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Tempest Extends Limited Duration Stockholder Rights Plan
Material agreement · Other events · EX-99.1 to Form 8-K
Tempest Reports Second Quarter 2024 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study
Material agreement · Other events · EX-99.1 to Form 8-K
Tempest Reports First Quarter 2024 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Tempest Reports Year End 2023 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Tempest Reports Third Quarter 2023 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Tempest Releases New Data Demonstrating Superiority of
Material agreement · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Tempest Adopts Limited Duration Stockholder Rights Plan
Material agreement · Charter or bylaw amendment · Other events · EX-99.2 to Form 8-K
Tempest Reports Second Quarter 2023 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Tempest Reports First Quarter 2023 Financial Results and
Results of operations · EX-99 to Form 8-K
Tempest Announces Positive Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120
Other events · EX-99.1 to Form 8-K
Tempest Reports Year End 2022 Financial Results and Provides
Results of operations · EX-99 to Form 8-K
Tempest Reports Third Quarter 2022 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Tempest Reports Second Quarter 2022 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Tempest Provides ASCO KOL Feedback on TPST-1120 Clinical Results and Updated Financial Guidance
Other events · EX-99.1 to Form 8-K
Tempest Reports Positive TPST-1120 Clinical Data from Phase 1 Trial in Patients with Advanced Solid
Other events · EX-99.1 to Form 8-K
Tempest Reports First Quarter 2022 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Tempest Announces Private Placement Financing of $15 Million
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Tempest Announces Oral and Poster Presentations at the Upcoming 2022 ASCO Annual Meeting
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Tempest Reports Year End 2021 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Tempest Reports Third Quarter 2021 Financial Results and
Results of operations · EX-99.1 to Form 8-K